Prospective randomized controlled trial of combination ranibizumab (lucentis) and bromfenac (xibrom) for neovascular age-related macular degeneration: A pilot study

Retina

Volumn 32, Issue 3, 2012, Pages 417-423

  Flaxel, Christina ^a   Schain, Mitchell B ^a   Hamon, Sara C ^b   Francis, Peter J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SELF ADMINISTRATION; DRY EYE; EYE BURNING; EYE DISEASE; EYE PAIN; EYE STINGIN; EYE STRAIN; EYELID DISEASE; HEADACHE; HUMAN; ITCHY EYE; ITCHY EYELID; LIGHT SENSITIVITY; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SORE EYELID; VIRAL CONJUNCTIVITIS; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZOPHENONES; BROMOBENZENES; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PILOT PROJECTS; PROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 84858069707     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318229b0af     Document Type: Article

References (23)

1. DAmico DJ. Diseases of the retina. N Engl J Med 1994;331: 95-106.
2. Rajappa M, Saxena P, Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem 2010;50:103-121.
3. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and agerelated macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-374.
4. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19: 361-372. (Pubitemid 44279358)
5. FerraraN, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-relatedmacular degeneration. Retina 2006;26:859-870. (Pubitemid 44547437)
6. Ozkiris A. Anti-VEGF agents for age-related macular degeneration. Expert Opin Ther Pat 2010;20:103-118.
7. Donoso LA, Vrabec T, Kuivaniemi H. The role of complement factor H in age-related macular degeneration: a review. Surv Ophthalmol 2010;55:227-246.
8. Augustin AJ, Kirchhof J. Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets 2009;13:641-651.
9. Eter N, Krohne TU, Holz FG. New pharmacologic approaches to therapy for age-related macular degeneration. BioDrugs 2006;20:167-179. (Pubitemid 43845337)
10. Eichler W, Yafai Y, Wiedemann P, Fengler D. Antineovascular agents in the treatment of eye diseases. Curr Pharm Des 2006; 12:2645-2660.
11. Constable I, Shen WY, Rakoczy E. Emerging biological therapies for age-related macula degeneration. Expert Opin Biol Ther 2005;5:1373-1385. (Pubitemid 41503048)
12. Heier JS, Awh CC, Busbee BG, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina 2009;29: 1310-1313.
13. Jones J, Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother 2009;10:2379-2385.
14. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010;30:260-266.
15. Zweifel SA, Engelbert M, Khan S, Freund KB. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2009;29:1527-1531.
16. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
17. NLME: Linear and Nonlinear Mixed Effects Models [computer program]. R package version 3.1-90; 2008.
18. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
19. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular agerelated macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-1469. (Pubitemid 350106676)
20. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65 e5.
21. Kiss CG, Geitzenauer W, Simader C, et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50: 2376-2383.
22. Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res 2010;91:537-543.
23. Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-536.